A rare scientific clinical trial involving cannabis-related compounds has produced stark evidence suggesting the medicinal benefits to be gained through controlled use of medical marijuana. Recently published results from a scientifically-conducted clinical trial show that treating young patients suffering from epilepsy with cannabidiol (“CBD”), a compound derived from marijuana, can significantly reduce and in some cases eliminate seizures in children and young adults. The study was published on May 25, 2017 in the New England Journal of Medicine1. It is among the first yielding substantiated clinical evidence to support a form of treatment that is becoming fairly widespread with the advent of medical marijuana.
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
The findings were derived from a double-blind, placebo-controlled study. “This study clearly establishes cannabidiol as an effective anti-seizure drug for this disorder and this age group,” reports Dr. Orrin Devinsky, the director of the